BioMarin Pharmaceutical (BMRN) shares ended the last trading session 6.3% higher at $59.43. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 20.7% loss over the past four weeks.The rise in share price came after President Trump announced a 90-day pause on his sweeping tariffs against non-retaliating countries.This rare disease biopharmaceutical is expected to post quarterly earnings of $0.95 per share in its upcomin ...

Core Viewpoint - BioMarin Pharmaceutical (BMRN) has received a Zacks Rank 2 (Buy) upgrade, indicating a positive outlook based on rising earnings estimates, which significantly influence stock prices [1][3]. Earnings Estimates and Stock Performance - The Zacks rating system emphasizes the importance of earnings estimate revisions, which are strongly correlated with stock price movements, particularly due to institutional investors' reliance on these estimates for valuation [4][6]. - BioMarin is projected to earn $4.30 per share for the fiscal year ending December 2025, reflecting a year-over-year increase of 22.2% [8]. Analyst Sentiment and Market Position - Over the past three months, the Zacks Consensus Estimate for BioMarin has increased by 9.6%, indicating a positive trend in analyst sentiment [8]. - The upgrade to Zacks Rank 2 places BioMarin in the top 20% of Zacks-covered stocks, suggesting potential for market-beating returns in the near term [10].

Core Insights - BioMarin Pharmaceutical Inc. announced positive results from its phase 3 Pegasus trial for its drug Palynziq (pegvaliase) aimed at treating patients with phenylketonuria (PKU) [2] Company Overview - BioMarin Pharmaceutical Inc. is focused on developing therapies for rare genetic diseases, with Palynziq being a significant product in its pipeline [2] Industry Context - The success of the Pegasus trial may enhance BioMarin's position in the biotech sector, particularly in the treatment of PKU, which is a rare metabolic disorder [2]

Company plans to submit for regulatory approval later this yearSAN RAFAEL, Calif., April 2, 2025 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that the Phase 3 PEGASUS trial evaluating PALYNZIQ® (pegvaliase-pqpz) met its primary efficacy endpoint, demonstrating a statistically significant lowering in blood Phe levels in adolescents aged 12-17 with phenylketonuria (PKU) compared to diet alone. Safety results were consistent with the known profile of the medicine. PALYNZIQ is the ...

Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both BioMarin Pharmaceutical (BMRN) and CSL Limited Sponsored ADR (CSLLY) . But which of these two stocks offers value investors a better bang for their buck right now? We'll need to take a closer look.The best way to find great value stocks is to pair a strong Zacks Rank with an impressive grade in the Value category of our Style Scores system. The proven Zacks Rank puts an emphasis on earnings estimates and esti ...

Core Viewpoint - BioMarin Pharmaceutical Inc. has appointed Timothy P. Walbert, former chairman, president, and CEO of Horizon Therapeutics, to its Board of Directors effective February 24, 2025 [1][2]. Group 1: Appointment Details - Timothy P. Walbert has over 30 years of experience in the pharmaceutical industry, having held leadership roles at various companies including IDM Pharma, NeoPharm Inc., and Abbott [2]. - Walbert led Horizon Therapeutics from its founding in 2008 until its acquisition by Amgen in 2023 and is currently a senior advisor at Amgen [2]. Group 2: Company Statements - Alexander Hardy, CEO of BioMarin, expressed enthusiasm about Walbert's appointment, highlighting his operational expertise and patient-centered approach [3]. - Walbert stated his commitment to BioMarin's strategy focused on innovation, growth, and value creation, emphasizing the importance of prioritizing patient needs [3]. Group 3: Company Overview - BioMarin is a global biotechnology company based in San Rafael, California, founded in 1997, with a focus on developing medicines for rare genetic conditions [4]. - The company has a strong track record of innovation, with eight commercial therapies and a robust clinical and preclinical pipeline [4].

Financial Performance - Total revenues for 2024 reached $2.9 billion, a 17.9% increase from $2.4 billion in 2023[360] - Net income for 2024 was $426.9 million, significantly up from $167.6 million in 2023, marking a 154.5% increase[360] - Total net product revenues for 2024 were $2.8 billion, an increase of $436.9 million compared to $2.4 billion in 2023[365] - Cash and cash equivalents rose to $942.8 million in 2024, an increase of $187.7 million from $755.1 million in 2023, while total cash, cash equivalents, and investments slightly decreased by $26.0 million[392] - Net cash provided by operating activities increased to $572.8 million in 2024 from $159.3 million in 2023, a rise of $413.5 million[394] - Net cash provided by investing activities improved to $136.5 million in 2024 compared to a net cash used of $(111.2) million in 2023, an increase of $247.7 million[395] - Net cash used in financing activities rose to $(526.4) million in 2024 from $(18.7) million in 2023, an increase of $(507.7) million primarily due to the $495.0 million settlement of the 2024 Notes[396] Sales and Revenue Drivers - VOXZOGO sales increased by $265.2 million, reaching $735.1 million in 2024, driven by higher sales volume from new patients[365] - KUVAN revenues decreased by $59.9 million in 2024 due to increased generic competition following the loss of market exclusivity[367] - The unfavorable impact of foreign currency exchange rates on product sales was $100 million in 2024, primarily due to the weakening of the Argentine Peso and Japanese Yen[371] Research and Development - Research and development expenses for 2024 were $747.2 million, slightly up from $746.8 million in 2023[360] - The company completed a strategic portfolio assessment to prioritize research and development programs with the strongest potential for success[363] - Research and early pipeline expenses rose to $434.0 million in 2024, up 40.9% from $393.1 million in 2023, primarily due to pre-clinical activities for new VOXZOGO indications[377] - Later-stage clinical program expenses decreased significantly by 56.4%, from $119.0 million in 2022 to $27.6 million in 2024, as ROCTAVIAN was moved to marketed products following FDA approval[377] Expenses - Total SG&A expenses increased to $1,009.0 million in 2024, up 13.1% from $892.4 million in 2023, with G&A expenses rising by 31.1% due to severance and restructuring costs[379][380] - Cost of sales for 2024 was $580.2 million, up from $532.1 million in 2023, reflecting higher sales volumes[373] - Other expense, net decreased from $38.2 million in 2023 to $4.7 million in 2024, primarily due to lower foreign currency transaction losses and decreased loss on non-marketable securities[386] Tax and Interest - Provision for income taxes surged to $114.9 million in 2024, a significant increase from $20.9 million in 2023, driven by higher earnings and foreign-source income taxed in the U.S.[387] - Interest income increased to $74.9 million in 2024, a 28.5% rise from $58.3 million in 2023, attributed to higher balances and yields on cash equivalents and investments[384] - Interest expense decreased to $12.7 million in 2024, down 26.6% from $17.3 million in 2023, primarily due to the maturity of convertible debt[385] Financial Obligations and Risks - As of December 31, 2024, the company had purchase obligations of approximately $641.9 million, with $482.0 million expected to be paid in 2025[400] - The company had lease payment obligations of $48.0 million as of December 31, 2024, with $9.5 million payable in 2025[401] - As of December 31, 2024, the company was subject to contingent payments of $258.1 million, with up to $3.1 million potentially payable in 2025[402] - The liability for unrecognized tax benefits was $325.0 million as of December 31, 2024[403] - Approximately 51% of net product sales were denominated in foreign currencies during 2024, exposing the company to foreign currency exchange rate risks[416] - A hypothetical 10% adverse movement in foreign currency exchange rates could reduce the value of open forward contracts by approximately $129.6 million[418] - A 100 basis point increase in interest rates could result in a potential loss in fair value of the investment portfolio of approximately $8.5 million[422] Financial Instruments and Hedging - The company mitigates foreign currency exchange rate risks through foreign currency derivative hedging transactions[414] - The company does not use derivative financial instruments for speculative trading purposes, focusing instead on risk management[417] - The company's financial risk management policy limits derivative transactions to institutions with minimum credit ratings of A- or equivalent[424]

Shares of BioMarin Pharmaceutical (BMRN) have gained 10.6% over the past four weeks to close the last trading session at $68.25, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $95.92 indicates a potential upside of 40.5%.The mean estimate comprises 25 short-term price targets with a standard deviation of $16.71. While the lowest estimate of $65 indicates a 4.8% decline from the ...

BioMarin Pharmaceutical (BMRN 4.75%) was a lively stock in the best way on Thursday following the release of its latest set of quarterly results. Enthusiastic investors traded the company's shares up by nearly 5% in price, contrasting quite sharply with the 0.4% decline of the S&P 500 index on the day.A pair of crushing beatsThose results were published just after market hours on Wednesday, and they showed that the company's revenue reached $747 million for its fourth quarter of 2024. That was a beefy (16%) ...

BioMarin Pharmaceutical (BMRN) reported fourth-quarter adjusted earnings per share of 92 cents, which beat the Zacks Consensus Estimate of 73 cents. Quarterly earnings rose 88% year over year, driven by higher product sales and lower operating expenses.Total revenues were $747.3 million, which rose 16% year over year on a reported basis and 21% on a constant-currency basis. Strong sales of Voxzogo drove this upside. The top line beat the Zacks Consensus Estimate of $711.9 million.See the Zacks Earnings Cale ...